Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:05:06 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



Q:ORGS - ORGENESIS INC - http://www.orgenesis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ORGS - Q4.60.525·0.57490.60.527+0.0051.075.6341620.5399  0.5796  0.5051.50  0.2519:43:51Apr 1515 min RT 2¢

Recent Trades - Last 10 of 162
Time ETExPriceChangeVolume
19:43:51Q0.525-0.01810
17:48:42Q0.525-0.01891
16:00:00Q0.5270.005617
16:00:00Q0.527-0.0168
16:00:00Q0.527-0.01614
16:00:00Q0.527-0.01613
16:00:00Q0.527-0.01612
16:00:00Q0.527-0.01611
16:00:00Q0.527-0.0169
16:00:00Q0.527-0.0169

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-15 17:07U:ORGSNews ReleaseOrgenesis Provides Year End Business Update
2024-04-10 12:00U:ORGSNews ReleaseGermfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
2024-03-18 08:30U:ORGSNews ReleaseVered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
2024-03-13 08:30U:ORGSNews ReleaseOrgenesis Consortium Awarded euros1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
2024-03-04 08:30U:ORGSNews ReleaseOrgenesis Inc. Announces $2.3 Million Private Placement
2024-02-29 08:30U:ORGSNews ReleaseOrgenesis Consortium Awarded euros2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
2024-01-31 09:15U:ORGSNews ReleaseOrgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
2023-11-14 08:30U:ORGSNews ReleaseOrgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
2023-11-13 16:16U:ORGSNews ReleaseOrgenesis Provides Business Update for the Third Quarter of 2023
2023-11-08 09:00U:ORGSNews ReleaseOrgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
2023-11-02 08:00U:ORGSNews ReleaseOrgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding
2023-10-30 21:30U:ORGSNews ReleaseOrgenesis Announces Withdrawal of Proposed Public Offering
2023-10-30 16:07U:ORGSNews ReleaseOrgenesis Announces Proposed Underwritten Public Offering
2023-09-21 08:00U:ORGSNews ReleaseCGT Global and Octomera Enter Agreement to Expand ‚  Cell & Gene Therapy Development and Patient Access Across the United States
2023-09-06 07:00U:ORGSNews ReleaseCell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support
2023-08-11 07:00U:ORGSNews ReleaseOrgenesis Provides Business Update for Second Quarter of 2023
2023-08-10 08:30U:ORGSNews ReleaseOrgenesis Schedules Second Quarter 2023 Business Update Conference Call
2023-07-13 08:30U:ORGSNews ReleaseOrgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer
2023-07-11 07:00U:ORGSNews ReleaseOrgenesis Announces Name Change of Morgenesis Business Unit to Octomera
2023-06-07 07:00U:ORGSNews ReleaseOrgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California